dpp-4 inhibitors vs. glp-1 agonist do not combine with receptor agonists guidance SGLT-2 inhibitors, GLP DPP4 Inhibitors vs GLP-1 Agonists
Description
The Promise of Tirzepatide: A Narrative Review of Metabolic Benefits
( Epub 2019/05/15 )
In addition to the aforementioned hypoglycemic, cardiovascular system protection, kidney protection, weight loss, and other effects, it was also found to have antitumor effects
Employers looking to add GLP-1 drug coverage specifically for weight loss to their health plans will be best-served by working in conjunction with clinical data experts who can help assess benefit design, address potential increases in drug spending, and incorporate healthcare benefits with effective behavioral modification and support programs
Recently, GLP-1RAs have been approved for the treatment of obesity and recognized for their cardioprotective effects
Recent evidence builds on the role that elements of diet, physical activity, and certain medications may play in depression risk
